Healthcare
Verrica Pharmaceuticals Inc.(VRCA)
Live Price
Offline$5.73
-4.90% today
1Y Change
-2.39%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +370.2%
- EPS Growth
- +88.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verrica Pharmaceuticals Inc. (VRCA) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $5.73 and down 2.4% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +370.2%, EPS growth of +88.6%, a dividend yield of 0.0%. What stands out right now is revenue +370.2%, EPS +88.6%, free cash flow +71.1% with operating margin -33.6% and ROIC -38.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRCA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+370.2% vs +7.6% peer median
Operating Margin
Below sector median
-33.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +370.2% and EPS at +88.6%, with operating margin around -33.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +3.1% | -21.8% | -19.6% |
2026 Mar 11, 2026 | -30.2% | -1.8% | -8.8% | -6.9% |
2025 Nov 14, 2025 | +111.4% | -5.1% | +7.1% | +92.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRCA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VRCA Max Drawdown
-62.43%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VRCA and SPY.
Company Overview
Verrica Pharmaceuticals Inc.
NASDAQ Global Market
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- Leadership
- Jayson Rieger
- IPO Date
- Jun 15, 2018
- Employees
- 71
- Street Address
- 44 West Gay Street
- Mailing
- West Chester, PA, 19380
- Region
- West Chester, PA, US
- Reporting Currency
- USD
- Investor Line
- 484 453 3300
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.9
- Price/Book
- 2.7
Growth
- Revenue
- +370.2%
- EPS
- +88.6%
- Free Cash Flow
- +71.1%
Profitability
- Gross Margin
- 90.8%
- Operating Margin
- -33.6%
- Net Margin
- -50.3%
- ROE
- 252.3%
- ROIC
- -38.0%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 2.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.